Navigation Links
BellBrook Labs Awarded NIH Grant to Develop a High Throughput cGAS Assay for Cancer and Autoimmune Disease Drug Discovery
Date:6/14/2017

The National Institutes of General Medical Sciences (NGMS) has awarded a Phase I $288,000 Small Business Innovative Research (SBIR) grant to BellBrook Labs, LLC for the commercialization of an innovative high throughput screening (HTS) assay for detecting cyclic GMP-AMP(cGAMP) the product of the cGAMP synthase (cGAS) enzyme.

cGAS is a novel target shown to have implications in immuno-oncology and autoimmune diseases. As foreign DNA enters the cell, cGAS detects the DNA and produces cGAMP, which acts as an agonist for the STING (stimulator of interferon genes) receptor to induce a type I interferon response. Researchers have shown that regulating cGAS activity could help control this immune response with therapeutic benefit for interferon-driven autoimmune diseases such as lupus. Progress discovering small molecule cGAS modulators have been slowed by the lack of HTS-compatible assays.

BellBrook has leveraged its proprietary Transcreener® platform to directly measure cGAMP in a homogeneous immunoassay format with fluorescent readouts. Direct detection reduces the potential for interference in HTS and allows kinetic methods such as determination of residence times for more effective lead optimization early in discovery. The Transcreener cGAS Assay will enable screening of diverse small molecules for an emerging target in autoimmunity and immuno-oncology, accelerating discovery of first-in-class drugs for debilitating diseases.

About BellBrook Labs:

BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions. Transcreener® is a universal, homogeneous biochemical assay platform based on detection of nucleotides that makes it easy to screen thousands of different enzymes. These include validated targets like kinases and phosphodiesterases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. Detection reagents and drug discovery services from BellBrook Labs help researchers progress toward more effective therapies for cancer and other debilitating diseases.

Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R43GM123833.The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Read the full story at http://www.prweb.com/releases/cGAS/Assay/prweb14421391.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. BellBrook Labs Webinar: Development of Ectonucleotidase Assay Methods Using the Transcreener® HTS Assay Platform
2. Top Accolades Awarded to Angry Citizen, Ecocat, Medesk and WESTUDY.IN At Challenge Cup Moscow
3. Puritan Medical Products Awarded Two New Flocked Swab Patents in Australia
4. Borrego Health Awarded $816,667 to Open Clinics in Anza and San Jacinto
5. Team of Chicago hospitals awarded grant to accelerate stroke research, treatments
6. Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
7. Steven Winter Associates, Inc. Awarded U.S. EPA's 2013 Indoor airPLUS Leader Award
8. Advanced Medical Awarded Recertification by the Joint Commission
9. Arminco, Inc. Awarded Contract to Design Alexandria Dental Office of Parker-Gray Pediatric Dental Care
10. Aequor Technologies Awarded Managed Services Contract to Provide Hardware Configuration and Deployment for Global Pharmaceutical Corporation
11. Kessler Foundation awarded grant to study self-generated learning in multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology: